Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.
Cannabis Law Report
AUGUST 10, 2021
This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. 2014; 7: 115-124. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. billion in 2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 28, 2021
Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit. Collect, track, and organize submission components using various document management systems to ensure high-quality and timely final submissions.
Cannabis Law Report
JULY 9, 2021
Collectively, private investors have poured billions of dollars into these companies, with more money coming from non-profit organizations. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.
Cannabis Law Report
JUNE 10, 2021
An alternative approach to study relationships between marijuana policies and driving after marijuana use is to use surveys that collect information on self-reported behaviors and attitudes. US traffic fatalities, 1985–2014, and their relationship to medical Marijuana Laws. JAMA Inter Med. 2020;54:69. Google Scholar. Lancet Psychiatry.
SMPL
MAY 26, 2020
Geoffrey Guy to develop plant-derived cannabis medicines; GW Pharmaceuticals licensed varietals bred from Mr. Watson and Mr. Clarke’s collection of cannabis and got to work. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. The Stanleys told me their wait-list peaked at 15,000 names.
Cannabis Law Report
NOVEMBER 24, 2021
Data collection. After the lull between 2002 and 2010, cannabis articles gather momentum, substantially increasing in 2014 and then gradually rising each year (with the exception of 2017 and 2018 which have the same number), with the highest rates seen between 2017 and 2019. Longitudinal frequency of articles about medicinal cannabis.
Expert insights. Personalized for you.
104 
Let's personalize your content